BioPhenoMA
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
BioPhenoMA develops ultrasensitive protein detection technology for oncology and immunology research, enabling quantification of trace proteins without specialized equipment.
OncologyImmunology
Technology Platform
TN-cyclon™ (improved enzyme cycling method) enables ultrasensitive protein detection (LOD <1 pg/mL) without specialized equipment by combining enzyme cycling with proprietary pretreatment and fractionation techniques that preserve biological structure.
Opportunities
Growing demand for protein biomarker discovery in precision oncology and immunology, plus potential applications in companion diagnostics and research tools for pharmaceutical companies.
Risk Factors
Early-stage platform company facing validation challenges, competition from established proteomics firms, and uncertain path to commercialization in crowded life sciences tools market.
Competitive Landscape
Competes with Olink, SomaLogic, and mass spectrometry-based proteomics platforms; differentiates through extreme sensitivity, equipment simplicity, and preservation of biological context during protein quantification.